Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease lennox-gastaut syndrome
Symptom C0036572|seizures
Sentences 25
PubMedID- 25051969 Rufinamide is a new antiepileptic drug approved for use as adjunctive therapy of seizures associated with lennox-gastaut syndrome and it is also effective for refractory partial seizures.
PubMedID- 25798598 The 1,5-benzodiazepine clobazam is indicated for the adjunctive treatment of seizures associated with lennox-gastaut syndrome in patients 2 years of age or older in the united states, and for treatment of anxiety and various forms of epilepsy elsewhere.
PubMedID- 21351809 The european commission and the us fda approved rufinamide in 2007 and 2008, respectively, for adjunctive treatment of seizures associated with lennox-gastaut syndrome in children 4 years of age or older and adults.
PubMedID- 21669560 Rufinamide is a triazole derivative structurally unrelated to other antiepileptic drugs that is indicated for the adjunctive treatment of seizures associated with lennox-gastaut syndrome (lgs) in patients aged >/=4 years.
PubMedID- 20150505 Background: rufinamide is an oral antiepileptic drug indicated for adjunctive therapy in treating generalized seizures associated with lennox-gastaut syndrome.
PubMedID- 21397780 Background: rufinamide is indicated for the adjunctive treatment of seizures associated with lennox-gastaut syndrome in patients aged >/=4 years.
PubMedID- 22332960 Rufinamide (inovelon(r)), a triazole derivative, is an oral antiepileptic drug approved in the eu as adjunctive therapy in the treatment of seizures associated with lennox-gastaut syndrome (lgs) in patients aged >/=4 years.
PubMedID- 20084538 Rufinamide was approved for the treatment of seizures associated with lennox-gastaut syndrome (lgs) as adjunctive therapy in patients aged 4 years and older.
PubMedID- 22128252 Clobazam as an adjunctive therapy in treating seizures associated with lennox-gastaut syndrome.
PubMedID- 22145708 In october 2011, clobazam (onfi; lundbeck inc., deerfield, il, usa) was approved by the us fda for use as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome in patients aged 2 years and older.
PubMedID- 24228152 Treatments of seizures for patients with the lennox-gastaut syndrome vary according to the predominant seizure type.
PubMedID- 23634191 Rufinamide is a novel anticonvulsant medication approved by the us food and drug administration (fda) in 2008 for the treatment of seizures associated with lennox-gastaut syndrome in patients 4 years of age and older, based upon clinical trials demonstrating clinical efficacy and tolerability.
PubMedID- 25132372 It is used to treat partial-onset seizures and seizures associated with lennox-gastaut syndrome (lgs) in adult and children.
PubMedID- 20233912 Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
PubMedID- 24533090 Clobazam (clb), a 1,5-benzodiazepine (bzd), was fda-approved in october 2011 for the adjunctive treatment of seizures associated with lennox-gastaut syndrome (lgs) in patients 2 years and older.
PubMedID- 21383651 Rufinamide (ruf) is an orphan drug for adjunctive treatment of seizures associated with lennox-gastaut syndrome in persons aged 4 years and older.
PubMedID- 21351810 Management of seizures in lennox-gastaut syndrome.
PubMedID- 24684645 Background: in october 2011, clobazam was fda-approved for adjunctive treatment of seizures associated with lennox-gastaut syndrome (lgs), a debilitating childhood epilepsy characterized by drop attacks, for patients 2 years and older.
PubMedID- 24712825 Later, it was approved for seizures associated with lennox-gastaut syndrome, generalized tonic clonic seizures, and as initial monotherapy for partial onset or primary generalized epilepsy.
PubMedID- 23034582 More recently, it was approved in the usa as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome in patients aged >/=2 years.
PubMedID- 20472190 The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with lennox-gastaut syndrome.
PubMedID- 20126329 In late 2008, the food and drug administration approved rufinamide for adjunctive use in the treatment of seizures associated with lennox-gastaut syndrome.
PubMedID- 25940107 Clobazam is equally safe and efficacious for seizures associated with lennox-gastaut syndrome across different age groups: post hoc analyses of short- and long-term clinical trial results.
PubMedID- 23112237 Despite worldwide usage, it was only recently approved in the united states (seizures associated with lennox-gastaut syndrome).
PubMedID- 21254787 Rufinamide, available as adjunctive treatment for seizures associated with lennox-gastaut syndrome, has an unclear mechanism of action, although it does block voltage-dependent sodium channels.

Page: 1